Revised. Amendments from Version 1
==================================

In response to reviewer comments, we clarified the inclusion of grey literature; corrected a typo in the search dates; and noted limitations around additional studies published since our review and the quality of studies included in the review.

Introduction
============

Vaccination coverage estimates are frequently used at the sub-national, national, and global levels to track performance, set priorities, make managerial and strategic decisions, and allocate funding for immunization programs ^[@ref-1]^. In some cases, vaccination coverage is continuously monitored through child-level registries, but these administrative sources are often unreliable, particularly in low and middle-income countries (LMIC) ^[@ref-2]^. Therefore, LMICs frequently complement administrative recording and reporting data with vaccination coverage surveys, which typically rely on documented evidence in home-based records (HBR) and/or caregiver recall to ascertain a child's vaccination history ^[@ref-3]--\ [@ref-5]^. In some cases, surveys also consult facility records, check for BCG scars, or analyze serological samples for evidence of immunity or prior vaccination ^[@ref-6],\ [@ref-7]^. However, there is no single gold standard for validating whether a child has been vaccinated and the accuracy of these sources for informing coverage estimates remains uncertain.

Multiple factors can cause each vaccination history source to over- or under-estimate coverage ^[@ref-8]^. Caregivers may over-report recalled vaccination histories due to social desirability bias or be unable to recall which and how many vaccinations their children received, particularly as vaccination schedules become more complex ^[@ref-9],\ [@ref-10]^. HBRs can be inaccurate if the record was not brought to every vaccination appointment or the provider made recording mistakes, including failing to record doses, recording doses that were not administered, or misrecording the vaccination date. Facility-based registries and records can be similarly incomplete. BCG vaccination typically leaves a characteristic scar as an indicator of vaccination; however 17 to 25% of vaccinated children may not develop a scar, independent of whether they develop immunity ^[@ref-11]^. Finally, while some consider serology the gold standard for measuring immunity to a disease, this differs conceptually from measuring receipt of a vaccine ^[@ref-12],\ [@ref-13]^. Immunization and vaccination status can differ for multiple vaccine or host-related factors including natural infection, lack of immune response to a vaccine, waning immunity, or deactivation of vaccines due to exposure to extreme temperatures ^[@ref-7]^. Furthermore, some serological assays may misclassify true immunization status due to innate performance limitations. Nevertheless, serological information can inform vaccination coverage estimates, particularly when it is possible to rule out or distinguish natural infection (tetanus, hepatitis B) or in settings where a disease has been eliminated (measles, rubella, or polio).

A review conducted by Miles *et al*. synthesized the literature comparing vaccination history obtained from HBR and recall to health provider-based sources for 1975--2011 ^[@ref-14]^. Compared to provider records, this review found that HBRs under-estimated coverage by a median of 13 percentage points (PP) (range: 61 PP lower to 1 PP higher), while recall over-estimated coverage by a median of 8 PP (range: 58 PP lower to 45 PP higher). The authors concluded that "household vaccination information may not be reliable, and should be interpreted with care." A review of five studies reporting on validity of caregiver recall (three of the studies were also included in the review by Miles *et al*. ^[@ref-14]^) conducted by Modi and colleagues observed mixed evidence regarding the its usefulness compared to documented evidence of vaccination history in HBRs ^[@ref-15]^. Most importantly, however, only five of 45 articles in the Miles and associates' review (and the two unique studies identified by Modi and colleagues) were conducted in LMICs. Given that immunization programmes located in LMICs are often the most reliant on survey data to help monitor programme performance and have the highest burden of vaccine-preventable diseases, the authors urged further research in these settings. Extending the inclusion criteria to include more sources of vaccination history and adding research from recent years provides a larger body of evidence from LMICs that should be analyzed. Furthermore, in a 2017 consultation by the World Health Organization (WHO), better understanding the reliability of recall was defined as one of the high research priorities around immunization ^[@ref-16]^.

We conducted a systematic review on the agreement between recall, HBR, health facility sources, BCG scars, and serological data in LMICs. We also investigated how agreement between these sources varies depending on factors including the type of vaccine, number of doses for a given vaccine, age of the child, and total doses in the country's vaccination schedule.

Methods
=======

Literature search
-----------------

We searched Medline and EMBASE for articles published from January 1, 1975 (aligned to the start of the EPI) through December 11, 2017. The search was restricted to human-related publications and included all languages. We adapted the search terms from the Miles *et al.* review to include additional terms about serology, and restricted to articles with an immunization/vaccination term in the title. We verified that all articles analyzed in the Miles review were found by our search. Articles needed to contain at least one term from each of the following three categories:

-   An immunization term in the title: *immunization\*, immunisation\*, vaccin\**;

-   An agreement term in the title, abstract, MeSH terms or keywords: *accuracy, bias, valid\*, reliab\*, misclassification, error, overestimate\*, underestimate\*, concordance, agreement, sensitivity, specificity, predictive value, comparing\*, compare\*, comparison\*, authentic\**;

-   A vaccination history term in the title, abstract, MeSH terms or keywords: *recall, remember, medical record\*, provider record\*, hospital record\*, clinical record\*, immunization record\*, immunisation record\*, administrative, card, cards, health booklet, health passport, maternal, parent\*, caregiver, mothers, registry, registries, register\*, household record\*, vaccination record\*, serosurvey, seroprevalence, serosurveillance, serological, biomark\*, scar\**.

Reviews and meta-analyses were not eligible, but their reference lists were manually reviewed, as were the references of each eligible article. We consulted with vaccination experts, including researchers and partners who attended an April 2017 WHO meeting on vaccination coverage surveys, to identify additional studies and unpublished analyses ^[@ref-17]^. The review protocol was created with feedback from experts.

The lead author screened all titles and abstracts, then reviewed the full text to confirm eligibility. Studies needed to meet several inclusion criteria. First, the review was restricted to LMIC, defined by the country's World Bank income classification for the respective years in which the published studies were conducted ^[@ref-18]^. Second, studies needed to report on vaccines administered to children under 5 years of age. Third, eligible studies had to report and/or compare vaccination status at the child-level from at least two sources, including: recall, HBR, a facility-based source, serological data (see details below) or BCG scar. One article used records from a prospective study where mothers reported their children's vaccinations on a weekly basis; those records were considered as health facility records. Serological studies were only included if the researcher could plausibly distinguish between immunity from vaccination and immunity from disease. This included tetanus, hepatitis B, and measles in non-measles endemic areas (as determined by the authors of each article). We excluded non population-based studies, including vaccine efficacy studies or studies among special populations such as pre-term infants.

Two researchers (ED and LS) independently extracted study meta data, measures of agreement, and findings on factors associated with agreement from each eligible study, using a pre-defined extraction template. Any discrepancies were discussed and reconciled between the two reviewers and the senior author.

Analysis
--------

We extracted the following measures for each pair of vaccination history sources in each eligible paper: percentage points (PP) difference in coverage (point estimates only), concordance, kappa statistic, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) ( [Table 1](#T1){ref-type="table"}). When papers did not explicitly report all measures, we attempted to calculate them using information provided in the papers. For example, if the paper reported a 2x2 table, we were able to calculate the desired measures of agreement, even if the author had not reported these in the paper. Sensitivity, specificity, PPV, and NPV require designating one source as the 'gold standard' or reference group; we used the same reference group(s) as chosen by the authors of each paper. However, we reiterate that in most settings there is no true gold standard for vaccination status to use as the reference. Therefore, these metrics should be interpreted as measures of agreement between two potentially flawed sources, as opposed to measures of validity compared to a gold standard.

###### 2×2 table comparing two sources of vaccination history, used to calculate measures of agreement.

  -------------------------------------------------------------------------------
                      Reference source\                          
                      (sometimes called 'gold\                   
                      standard')                                 
  ------------------- -------------------------- --------------- ----------------
  Comparator source   \+                         True positive   False positive

  \-                  False negative             True negative   
  -------------------------------------------------------------------------------

###### Definitions of measures of agreement.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Measure                 Definition                                                             Calculation
  ----------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------------------
  **PP difference in**\   Difference between coverage level estimated by the two sources         $$Coverage_{Comparator} - Coverage_{Reference}$$
  **coverage**                                                                                   

  **Concordance**         \% of children with the same vaccination status from both sources      $$\frac{True\ Negative + True\ Positive}{Total\ Children}$$

  ***Kappa* statistic**   Measure of concordance that corrects for chance agreements.\           $$\frac{Observed\ Agreement - Expected\ agreement}{1 - Expected\ Agreement}$$
                          Interpretation: \<0.2 = poor; 0.21-0.4 = fair; 0.41-0.6 = moderate;\   
                          0.61-0.8 = substantial; 0.81-1.0 = near perfect                        

  **Sensitivity**         \% of children vaccinated according to the reference source that\      $$\frac{True\ Positive}{True\ Positive + False\ Negative}$$
                          are vaccinated according to the comparator source                      

  **Specificity**         \% of children unvaccinated according to the reference source\         $$\frac{True\ Negative}{True\ Negative + False\ Positive}$$
                          that are unvaccinated according to the comparator source               

  **Positive**\           \% of children vaccinated according to the comparator source\          $$\frac{True\ Positive}{True\ Positive + False\ Positive}$$
  **predicative**\        who were vaccinated according to the reference source                  
  **values**                                                                                     

  **Negative**\           \% of children unvaccinated according to the comparator source\        $$\frac{True\ Negative}{True\ Negative + False\ Negative}$$
  **predictive values**   who were unvaccinated according to the reference source                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

For articles reporting on multiple countries or sub-regions within a country, we treated each geographic region as a separate study population.

For articles reporting on multiple age groups, we used the group closest to 12--23 months in the main analyses, and subsequently conducted a separate analysis of how agreement varied for different age groups within a given study.

Similarly, for articles reporting on multiple doses of the same antigen, we present the results for the most commonly reported dosages in the main analysis, and subsequently conducted a separate analysis of how agreement varied for different doses of the same antigen within a given study. The most common antigen-doses were: Bacille Calmette-Guerin (BCG), 1 ^st^ dose Measles-Containing Vaccine (MCV1), 1 ^st^ dose Oral Polio Vaccine (OPV1), and 1 ^st^ and 3 ^rd^ dose Diphtheria Tetanus Pertussis (DTP), including any DTP-containing combination vaccine. When reported, we also included summary measures for if the child was Up to Date (UTD) on vaccinations for their age, according to the definition used in the original study (with the limitation that that variation in age groups across studies could act as a confounder in the UTD metric).

Analyses were conducted using StataSE 15 and R version 3.3.1.

Results
=======

Search results
--------------

The Medline and EMBASE searches identified a total of 4420 unique titles ( [Figure 1](#f1){ref-type="fig"}). 10 additional titles were identified by experts, and 2 were identified by manually reviewing references. This totaled to 4432 titles, of which 313 passed title and abstract screening and 27 were eligible for the study. Of these, 6 articles were published prior to 2000, 10 from 2000--2009, 8 from 2010--2017, and 3 were unpublished findings provided directly by researchers identified through the expert network ( [Table 2](#T2){ref-type="table"}). One study contained information on two countries, and one presented results for three sub-national regions, resulting in a total of 30 study sites. 11 study sites were in the World Health Organization (WHO) African region, 5 in the Americas, 4 in the Eastern Mediterranean, 8 in South-East Asia and 2 in Western Pacific ^[@ref-19]^. 15 study sites reported on MCV, 14 on DTP, 10 on BCG, 2 on OPV, and 1 on pneumococcal conjugate vaccine (PCV). Three reported on measures of UTD.

![Article screening.](gatesopenres-3-14264-g0000){#f1}

###### Articles included in the systematic review.

  -------------------------------------------------------------------------------------------------------------------------------
       First Author                         Published        Location        Survey\       Vaccines     Sources of\
                                                                             period                     vaccination data
  ---- ------------------------------------ ---------------- --------------- ------------- ------------ -------------------------
  1    Aaby ^[@ref-20]^                     1998             Guinea-Bissau   1998          MCV          Facility, recall

  2    Adedire ^[@ref-21]^                  2016             Nigeria         2013          UTD          HBR, recall

  3    Colson ^[@ref-22]^                   2015             Mexico,\        2012 - 2013   MCV          HBR, serology
                                                             Nicaragua                                  

  4    Dunem ^[@ref-23]^                    2010             Angola          2005 - 2006   BCG          HBR, recall, scar

  5    GAVI FCE ^[@ref-24]^                 Unpublished      Uganda          2015          DTP, PCV     HBR, recall,\
                                                                                                        HBR+recall, serology

  6    GAVI FCE ^[@ref-24]^                 Unpublished      Zambia          2015          DTP          HBR+recall, serology

  7    Gareaballah ^[@ref-25]^              1989             Sudan           1998          MCV          HBR, recall

  8    George ^[@ref-26]^                   2017             India           2015          DTP          HBR, recall

  9    Gong ^[@ref-27]^                     Unpublished      Pakistan        2016          MCV          HBR, HBR+recall,\
                                                                                                        serology

  10   Hayford ^[@ref-28]^                  2013 (author\    Bangladesh      2010 - 2011   BCG, DTP,\   Facility, HBR, recall,\
                                            provided data)                                 MCV, OPV     HBR+recall, serology

  11   Jahn ^[@ref-29]^                     2008             Malawi          2002 - 2004   BCG          HBR, scar

  12   Langsten ^[@ref-30]^                 1998             Egypt           1990 - 1991   BCG, DTP,\   HBR, recall
                                                                                           MCV          

  13   Liu ^[@ref-31]^                      2017             China           2009 - 2015   MCV          Facility, recall

  14   Luman ^[@ref-32]^                    2009             N Mariana\      2005          UTD          Facility, HBR, recall,\
                                                             Islands                                    HBR+recall

  15   Mast ^[@ref-33]^                     2006             Uganda          Not given     DTP, MCV     HBR, recall

  16   Murhekar ^[@ref-34]^                 2017             India           2015          BCG, DTP,\   HBR, recall
                                                                                           MCV, UTD     

  17   Nanthavong ^[@ref-35]^               2015             Lao             2013          DTP          HBR, serology

  18   Pereira ^[@ref-36]^                  2001             Brazil          Not given     BCG          HBR, recall, scar

  19   Ramakrishnan ^[@ref-37]^             1999             India           Not given     BCG, DTP,\   Facility, recall
                                                                                           MCV, OPV     

  20   Ruiz-Gomez ^[@ref-38]^               2007             Mexico          1999 - 2000   MCV          HBR, serology

  21   Selimuzzaman ^[@ref-39]^             2008             Bangladesh      Not given     MCV          HBR, recall

  22   Sinno ^[@ref-40]^                    2009             Lebanon         2003          UTD          Facility, recall

  23   Srisaravanapavananthan ^[@ref-41]^   2008             Sri Lanka       2006          BCG          HBR, scar

  24   Tapia ^[@ref-42]^                    2006             Mali            Not given     DTP          HBR+facility, serology

  25   Travassos ^[@ref-43]^                2016             Ethiopia\       2013          DTP          Facility, HBR, recall,\
                                                             (3 regions)                                serology

  26   Ullah ^[@ref-44]^                    2000             Bangladesh      Not given     BCG, MCV     Facility, recall

  27   Valadez ^[@ref-45]^                  1992             Costa Rica      1987          BCG, DTP,\   HBR, recall
                                                                                           MCV, OPV     
  -------------------------------------------------------------------------------------------------------------------------------

Agreement of sources for all childhood vaccines assessed
--------------------------------------------------------

[Recall vs. HBR:]{.ul} Ten papers compared vaccination status based on recall to HBR ( [Table 3](#T3){ref-type="table"}). The median percentage point difference in coverage estimated using the two was small (1 PP), but ranged from -43 to +17 PP. Recall-based coverage estimates were higher than those based on HBR for 12 of 18 data points, but were only over 10 percentage points higher in 3 cases ( [Figure 2](#f2){ref-type="fig"}). Median kappa (.55) and concordance (.88) between vaccination status based on recall and HBR were substantially higher than any other comparison, and kappa exceeded .60 ("substantial agreement") 45% of the time ( [Figure 3](#f3){ref-type="fig"}). PPV, sensitivity, NPV and specificity exceeded 80% in 94%, 81%, 56%, and 38% of cases, respectively.

###### Summary measures of agreement for standard childhood vaccines and doses, including BCG, DTP3, MCV1, OPV1, PCV1, Yellow Fever (YF) and UTD.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          N\         N\     PP diff in\       *Kappa*                Sensitivity           Specificity           Concordance           PPV                   NPV
                          articles   data   coverage\                                                                                                                        
                                            est.                                                                                                                             
  ----------------------- ---------- ------ ----------------- ---------------------- --------------------- --------------------- --------------------- --------------------- ---------------------
  **Recall vs. HBR**      10         24     1 (-43 to 17)     0.55 (0.00 to 0.88)    0.95 (0.46 to 1.00)   0.73 (0.00 to 1.00)   0.88 (0.53 to 0.98)   0.93 (0.64 to 0.99)   0.83 (0.07 to 1.00)

  **Recall vs. HF**       7          14     5 (-29 to 34)     0.18 (-0.01 to 0.57)   0.89 (0.51 to 1.00)   0.50 (0.00 to 0.76)   0.78 (0.50 to 0.94)   0.80 (0.49 to 0.99)   0.44 (0.20 to 0.86)

  **HRB vs. HF**          2          5      17 (-61 to 21)    0.00 (-0.12 to 0.06)   0.95 (0.32 to 0.99)   0.01 (0.01 to 0.91)   0.77 (0.38 to 0.77)   0.78 (0.78 to 0.98)   0.20 (0.01 to 0.27)

  **HBR + recall**\       2          5      14 (-40 to 20)    0.01 (-0.05 to 0.07)   0.94 (0.53 to 1.00)   0.05 (0.00 to 0.69)   0.77 (0.54 to 0.80)   0.80 (0.79 to 0.94)   0.17 (0.13 to 0.50)
  **vs. HF**                                                                                                                                                                 

  **Recall vs.**\         2          7      -20 (-32 to 2)    0.26 (0.13 to 0.71)    0.23 (0.09 to 0.99)   0.90 (0.56 to 1.00)   0.73 (0.56 to 0.95)   0.95 (0.33 to 1.00)   0.79 (0.68 to 0.86)
  **serology**                                                                                                                                                               

  **HBR vs.**\            5          14     2 (-38 to 36)     0.21 (0.00 to 0.84)    0.91 (0.50 to 1.00)   0.44 (0.00 to 1.00)   0.79 (0.54 to 0.95)   0.93 (0.57 to 1.00)   0.52 (0.07 to 0.83)
  **serology**                                                                                                                                                               

  **HBR + recall vs.**\   3          4      -10 (-36 to 14)   0.21 (0.02 to 0.48)    0.79 (0.60 to 0.91)   0.48 (0.38 to 0.65)   0.69 (0.60 to 0.88)   0.92 (0.69 to 0.96)   0.33 (0.05 to 0.70)
  **serology**                                                                                                                                                               

  **HF vs. serology**     2          7      0 (-3 to 4)       0.05 (-0.09 to 0.23)   0.80 (0.62 to 0.93)   0.33 (0.04 to 0.60)   0.67 (0.60 to 0.88)   0.87 (0.71 to 0.94)   0.28 (0.03 to 0.40)

  **HF + HBR vs.**\       1          4      7 (-6 to 20)      0.00 (-0.1 to 0.00)    0.97 (0.93 to 1.00)   0.00 (0.00 to 0.00)   0.87 (0.74 to 1.00)   0.90 (0.79 to 1.00)   0.00 (0.00 to 0.00)
  **serology**                                                                                                                                                               

  **HBR vs. scar**        3          3      11 (-4 to 11)     0.08 (0.00 to 0.31)    0.94 (0.85 to 1.00)   0.21 (0.00 to 0.54)   0.89 (0.67 to 0.93)   0.89 (0.74 to 0.98)   0.30 (0.25 to 0.36)

  **Recall vs. scar**     1          1      2 (2 to 2)        0.43 (0.43 to 0.43)    0.93 (0.93 to 0.93)   0.48 (0.48 to 0.48)   0.86 (0.86 to 0.86)   0.91 (0.91 to 0.91)   0.54 (0.54 to 0.54)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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[Recall vs. Facility Records:]{.ul} Seven papers compared recall to health facility records. Recall-based coverage estimates were higher than those based on facility records in 9 of 14 comparisons, 5 of which exceeded +10 percentage points. The median PP difference was +5 PP. Median concordance was .78, and exceeded .80 for 29% of comparisons. Median kappa was .18, and never exceeded .60. Median sensitivity (.85) and PPV (.80) were higher than median specificity (.50) and NPV (.44).

[HBR vs. Facility Records:]{.ul} Two papers compared HBR to facility records. Coverage estimates based on HBR were a median of 17 PP higher than those based on facility records, though the range was wide (-61 PP to +21 PP). Most measures of agreement were weak, including a median kappa of 0.00, specificity of 0.01 and NPV of 0.20. Concordance (median=0.77) never exceeded 0.80. Median sensitivity (0.95) and PPV (0.78) were relatively higher.

[Recall + HBR vs. Facility Records:]{.ul} The same two studies that compared HBR to facility records also compared combined recall and HBR to facility records, with similar results as those noted above for the HBR vs facility records comparison.

[Recall vs. Serology:]{.ul} Two papers including four study sites compared recall to serology. This included one article studying MCV1 vs. measles immunoglobulin G (IgG) and one article (with three study sites) studying pentavalent DTP-Hepatisis B (HepB)- *Haemophilus influenzae* type b (Hib) coverage compared to tetanus IgG and Hib polyribosylribitol phosphate (PRP) antibodies. In the pentavalent DTP-HepB-Hib study, recall consistently under-estimated compared to serology (range: -32 PP to -13 PP), while coverage estimates were similar in the MCV1 study (2 PP higher according to recall). Kappa showed substantial agreement in the measles study (0.71), and ranged from 0.13 to 0.65 in the pentavalent DTP-HepB-Hib study. NPV (median: 0.79, range: 0.68 to 0.86) and specificity (median: 0.90, range: 0.56 to 1.0) were high relative to other types of comparisons, while PPV (0.33 to 1.00) and sensitivity (0.09 to 0.99) varied widely.

[HBR vs. Serology:]{.ul} Five papers including eight study sites compared HBR to serology. One study compared DTP to diphtheria and tetanus antibodies, one compared Pentavalent (with DTP as a proxy) to tetanus and Hib antibodies, and three compared to measles antibodies. Coverage based on HBR was a median of 2 PP higher than serologically-confirmed coverage, but the difference ranged from -38 PP to +36 PP. Other measures of agreement also varied widely across the studies and antigens.

[Recall + HBR vs. Serology:]{.ul} Three papers compared combined recall and HBR to serology, including two comparing DTP3 to tetanus antibodies and two comparing MCV1 to measles antibodies. Recall + HBR under-estimated DTP3 coverage in both cases (-15 to -36 PP). Recall + HBR over-estimated MCV1 coverage for the one study (+14 PP) and under-estimated in the other (-4 PP). Kappa, sensitivity and NPV were higher in the MCV1 studies than the DTP3 studies.

[Facility Records vs. Serology:]{.ul} Two papers containing four study sites compared facility records to serology, including a measles serum study in Bangladesh and a tetanus antibody study in Ethiopia. There was almost no difference in the population-level tetanus estimates for the three sites in Ethiopia (range: -1 to +4 PP) or the measles study in Bangladesh (-3 PP). Kappa was low (median: 0.05, range: -0.09 to 0.23). Sensitivity and PPV tended to be higher than specificity and NPV.

[Facility Records + HBR vs. Serology:]{.ul} One paper compared tetanus serum and tetanus oral fluid to combined facility record and HBR information in Mali. In the 12--23 month-old group, it found that the Facility Record + HBR over-estimated coverage compared to the oral tetanus test by 14 PP, but under-estimated by 6 PP compared to the serum. Sensitivity and concordance was high for both, but the kappa and NPV were zero (or nearly zero).

[BCG Scar studies:]{.ul} Four papers reported on BCG scars. Three compared HBR to BCG scars (with scars as the gold standard) and one compared recall to scars. HBR estimated 11 PP higher coverage than scars in one case and 4 PP lower in another, and kappa ranged from 0.00 to 0.31. Sensitivity was high (0.85 to 1.00), but specificity low (0.21 to 0.54). From the one data point available, recall estimated 2 PP higher coverage than scars, with high sensitivity (0.93) but lower specificity (0.48).

Factors associated with vaccination agreement between data sources
------------------------------------------------------------------

[Variation by coverage level:]{.ul} When interpreting results, it is important to note that some measures of agreement are inherently affected by the level of vaccination coverage estimated by the reference source. According to mathematical principles, concordance tends to be lowest at 50% coverage and highest at the extremes; PPV increases with coverage; and NPV decreases with coverage. In contrast, kappa, sensitivity and specificity are not affected by vaccination coverage levels. These principles are visibly reflected when comparing agreement measures across studies and vaccines with different coverage levels ( [Figure 4](#f4){ref-type="fig"}). However, there is also confounding by factors such as the study setting, types of sources being compared, and type of vaccine. For example, in settings with \>=75% coverage, very few data points report NPV above 0.5, with the exception of some comparing recall to HBR.

![Relationship between coverage level and measures of agreement.\
HBR: Home-Based Record, HF: Health Facility, PPV: Positive Predictive Value; NPV: Negative Predictive Value; PP: Percentage Point.](gatesopenres-3-14264-g0003){#f4}

[Variation by antigen:]{.ul} Four studies compared recall to HBR for multiple antigens. In all three cases where PP difference could be calculated, DTP3 coverage was underestimated (-45, -14, and --7 PP) more than any other vaccine or dose ( [Figure 5](#f5){ref-type="fig"}). While DTP3 also had the lowest concordance (and BCG the highest), this was explained in part by chance agreement, and no antigen had consistently higher or lower kappa.

![Variation in percentage point difference and kappa for different antigens reported in the same study.](gatesopenres-3-14264-g0004){#f5}

Three studies compared recall to facility records for multiple antigens. Two of the studies included DTP3, and DTP3 had the lowest kappa in both (0.50 and 0.57).

[Variation by number of doses:]{.ul} [Figure 6](#f6){ref-type="fig"} depicts data from five studies that reported on multiple doses of the same antigen, allowing us to analyze how agreement varies by dose. Lines connect points showing a different number of doses for the same antigen, type of comparison, and study site. In nearly all studies, the non-gold standard tends to over-estimate compared to the gold-standard for 1 dose, then come closer to the gold-standard value or even estimate lower coverage than the gold --standard at 2 and 3 doses. Kappa values decrease at higher doses in most studies, with the exception of a study comparing DTP from HBR to diphtheria and tetanus serology in Laos ^[@ref-35]^. Results are level or inconsistent for PPV and NPV across doses.

![Variation in percentage point difference and kappa for different doses of the same antigen.\
Each point represents a different number of doses for an antigen, and each line connects points for the same antigen, source and study.](gatesopenres-3-14264-g0005){#f6}

[Variation by child age:]{.ul} [Figure 7](#f7){ref-type="fig"} shows the variation in agreement and recall between sources depending on the age of the child, using data from three of the previously described studies that stratified results for the same vaccine dose by age. Lines connect points showing different age groups for the same vaccine/dose and study site. In the Langsten study, the kappa of recall compared to HBR decreases with age. In the Tapia study, kappa for HBR or health facility record compared to serology decreases with age. In the Luman study, kappa for recall and/or HBR measuring UTD vaccination compared to facility records increase from 12--23 to 24--35 month-olds, but then decrease for 72--83 month-olds.

![Variation in percentage point difference and kappa by age group.\
Each point represents an age group for a given antigen/dose. Each line connects points for the same antigen/dose, comparison type and study.](gatesopenres-3-14264-g0006){#f7}

[Variation by schedule complexity:]{.ul} It has been hypothesized that increasingly complex national vaccination schedules reflecting recommendations by WHO ^[@ref-10]^ make it more difficult for caregivers to accurately recall their child's vaccination history, particularly the number of doses received for multi-dose vaccines. We did not observe a clear, consistent relationship between the number of doses in the national vaccination schedule and the percentage point different in coverage estimates or the kappa statistic for recall as compared to HBR, facility records or serology ( [Figure 8](#f8){ref-type="fig"}) though there were relatively few studies available at periods of time when the national schedule recommended twelve or more vaccines.

![Relationship between number of doses in national schedule and ( **a**) percentage point difference in coverage; ( **b**) kappa.](gatesopenres-3-14264-g0007){#f8}

[Demographic and other factors associated with agreement:]{.ul} Two studies analyzed factors associated with agreement. A study comparing recall to HBR in Costa Rica found that having more doses on the card (correlation coefficient: -0.61) and being an older child (correlation coefficient: -0.35) were associated with smaller error with a p-value\<0.0001, while factors including community health worker visits, being recorded in health center records, household size, maternal age and education and socioeconomic status were not significant at the 0.0001 level (specific p-values were not provided) ^[@ref-45]^. In India, a study comparing recall to ongoing prospective reporting found that agreement was higher for younger mothers (1.7 fold increase, p=0.03) ^[@ref-37]^. Other factors including "father\'s age, sex of the child, place of dwelling, parity, mother\'s education, family size, previous sibling status and mother\'s occupation" were not significantly associated with agreement.

Discussion
==========

Our study finds relatively good agreement between vaccination based on documented evidence in HBRs and that obtained from recall, but comparatively poor agreement versus facility-based records or serology in LMIC settings. Agreement varied substantially depending on the study setting, coverage level, type of antigen, number of doses, and child age.

These findings may be used to heighten awareness and inform discussions about the limitations of survey-based coverage estimates. Survey data have been treated as a 'gold standard' to validate or adjust administrative coverage sources, but this assumption may not always be appropriate ^[@ref-46]--\ [@ref-48]^. Furthermore, countries with weak administrative systems for coverage estimation are often the same countries where card availability is low and surveys have to rely more on recall ^[@ref-49]^. Those using survey-based vaccination coverage should carefully consider the quality of data underlying the estimates for their specific context(s). For example, current HBR availability has been found to vary considerably across Demographic and Health Surveys (DHS) conducted since 2010 ^[@ref-50]^. Facility registries are also far more complete and accurate in some countries compared to others, and the ease to use them also varies depending on how they are organized (by date of birth, vs date of vaccination visit for example) ^[@ref-51]^. Additionally, while we did not observe that recall validity is changing over time, we believe this remains an open research question, including the influence of different factors including increasing national vaccination schedule complexity ^[@ref-52]^ further complicated by decreasing fertility ^[@ref-53]^ and changing patterns in maternal education ^[@ref-54],\ [@ref-55]^. In order for decision makers to weigh these potential limitations, it is incumbent on those conducting surveys to be clear and thorough in the documentation of their work, including the limitations. Developing a standard template for vaccination coverage survey reports might further support this need for improved transparency.

We also believe additional steps can be taken during the survey design and data collection process to improve available information collected from respondent recall of child vaccination history. For example, DHS and UNICEF Multiple Indicator Cluster Surveys (MICS) currently require respondents to recall the number of doses the child has received for multi-dose vaccines (after obtaining an affirmative response that the child received the multi-dose vaccine). A response of "I don't know" is most often not available in the standard response set. By requiring a numerical response (e.g., 0, 1, 2, 3 doses), even when the "true" response is "I don't know", respondents and enumerators are forced to undertake an ill-understood, unstandardized imputation processes in the field. The classification of "don't know" responses has been shown to affect coverage estimates by nearly 20 percentage points ^[@ref-25]^. Allowing "don't know" responses would improve transparency around this important element of uncertainty and empower survey data users to impute in a more systematic way. Surveys might also explore collecting vaccination history from both caregiver recall (asked first of all respondents) and HBRs for all survey respondents, as done in some of the studies included in our review, in order to better assess recall validity among the subset with information from both sources and reveal the directionality and drivers of bias for that particular survey setting.

Despite their limitations and biases, surveys can and will continue to be an important source of information on vaccination programs. As emphasized in the recently updated WHO Survey Reference Manual, surveys will be most useful when they are designed to answer explicit questions ^[@ref-4]^. Clarity about the goals of a survey also gives context to the strengths and limitations of different ascertainment methods and whether additional precision and associated expenses are needed. For example, HBR and recall-based coverage estimates might be considered "good enough" for measuring global or national trends, even if they may over or under-estimate coverage or have poor child-level validity. However, the same data could be inappropriate for measuring achievement against results-based financing goals, as cautioned by the WHO's Strategic Advisory Group of Experts on Immunization in 2011 ^[@ref-56]^. Greater precision may also be needed to detect change in high-coverage settings ^[@ref-57]^. HBR and recall-based histories could also be problematic if a goal is to monitor equity across socioeconomic groups, as HBR availability and recall bias can vary by the same socioeconomic characteristics that are associated with vaccination coverage; more research is needed on this topic given the recent global emphasis on monitoring equity ^[@ref-58],\ [@ref-59]^. Of course, survey objectives are often more complicated than the examples given here -- a survey may have multiple goals or multiple stakeholders each with their own goals. National immunization programs and other survey implementers could benefit from additional WHO guidance about what type of survey design is most appropriate, if at all, given their specific objectives and available data conditions.

Particularly strong clarity about survey goals is needed to justify the added cost and effort of collecting serological samples, as well as to interpreting those findings ^[@ref-7]^. Across included studies, we find substantial discordance between serology and HBR or recall. This is expected given that serology measures something conceptually different than HBR and recall and reinforces that HBR and recall are poor proxies when a survey needs to measure immunization status, as opposed to vaccination status, of a population. Serology has an obvious added value when a decision should be based on population immunity, for example for disease elimination purposes ^[@ref-13],\ [@ref-60]^. However, if the goal is to gather information on vaccination service utilization and dropout, a serosurvey might be difficult and time-consuming to implement and analyze, unnecessary and ultimately wasteful. As methods for collecting and analyzing serology become cheaper, easier and more accurate, researchers and public health officials should continue to explore potential applications, such as using serosurveys to trigger campaigns ^[@ref-61]^.

The intended use of a survey should also guide which specific vaccines are emphasized for analysis and reporting. DTP3 is frequently used as a standard indicator of immunization program performance ^[@ref-62]^. However, DTP3 recall (as compared to HBR and facility sources) is found to have lower concordance and under-estimate coverage by more percentage points than other vaccines in several studies. Therefore, survey users should consider examining other vaccines and doses if precise estimates are needed for decision-making. At the same time, DTP3 may be the most appropriate if the goals are oriented towards measuring delivery and retention in the routine immunization program, given that vaccines such as MCV are often delivered through campaigns in addition to routine immunization. However, the DTP retention metric or dropout (commonly calculated as the relative difference between DTP1 and DTP3 coverage) should still be interpreted with caution given our finding that bias may differ for the 3 ^rd^ versus 1 ^st^ dose.

Finally, the large inconsistencies between home and facility-based records when compared to each other, recall, and serology demonstrate inadequate information for health providers for determining which children have and have not been vaccinated. It is important to be aware that each of these sources is imperfect. Indeed, the primary purpose of these data sources is to serve frontline workers, rather than inform coverage surveys ^[@ref-63]^. Without accurate and complete documentation of children's vaccination histories, vaccinators will continue to miss opportunities to catch up unvaccinated children as well as waste resources re-vaccinating those who may already be protected ^[@ref-64]^. Such inefficiencies would likely be considered unacceptable in the private sector or other economic fields, and may be overcome using human centered design ^[@ref-65],\ [@ref-66]^ and other innovative approaches to optimize existing immunization programme resources ^[@ref-67]^.

Our study is subject to several limitations. First, although we believe our literature search to be comprehensive, it is possible relevant studies were not identified. In particular, EMBASE and our expert network may not have captured all relevant grey literature. Further, this is an active area of research, and additional studies on the topic have been published since our review cut-off date in December 2017 that provide additional information. As a case in point, a similar yet distinct review of caregiver recall was published as this manuscript was being finalized ^[@ref-15]^. Second, the articles included in our review frequently reported data in inconsistent ways. We made every effort to ensure comparability across studies, but in some cases, we were missing necessary information about methodological or analytical details. For example, not all studies specified how they treated "don't know" responses from respondents when asked about their child's vaccination history and there were possible inconsistencies in how different authors counted the dose of polio recommended at birth (polio 0), when in the schedule. We also only focused on point estimates, thus, not taking into account sampling errors. Additionally, we expect there is special difficulty in differentiating vaccination received through routine delivery of vaccination versus campaign doses, including for MCV. As this issue was often not discussed by the source articles, it may not be well-addressed in our study. Most articles also did not document the phrasing of vaccination history recall questions; studying the best way to solicit recall, including the use of visual cues, is an area for future research. Some of these limitations may be addressed through further analysis of existing data, which the researchers approached as part of this review were agreeable to do. Finally, we did not include an assessment of the quality of each study. The level of detail provided about the survey design, data collection, and analysis methods varied substantially across studies. Going forward, the WHO is working to define clearer quality criteria for surveys measuring vaccination coverage, which could serve as a benchmark and standardize reporting. We did take special effort to assess the quality of un-published work before including these in the review, by speaking directly with the researchers to understand the design, implementation, and limitations of their studies.

In conclusion, while recall and HBR provide relatively concordant vaccination histories in some settings, both have poor agreement when compared to facility-based records and serology. In the long-term, improving clinical decision making for immunization and survey-based vaccination coverage estimates will depend on strengthening administrative systems, recording practices and record keeping. In the short-term, there must be greater recognition of imperfections in current ascertainment techniques, paired with explicit clarity regarding the goals of surveys and the level of precision, potential biases, and associated resources needed to achieve these goals.
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I read the revised version of the systematic review by Emily Dansereau and colleagues with great interest. The authors conducted a systematic review of peer-reviewed literature published from 01 January 1975 to 11 December 2017. They found that vaccination data from caregiver recall were concordant with those from home-based records; but both had poor agreement with coverage data from facility-based records and serology. They took all our previous comments into consideration when revising the article and I have no further comments. This is a policy- and research-relevant publication. Well done.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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We commend Emily Dansereau and colleagues for conducting this timely systematic review on the agreement between recall, home-based records, health facility sources, BCG scars, and serological data in low and middle-income countries. While we applaud the efforts of the authors, we think the review could be improved, as follows: The authors indicate that they prepared a protocol for the review but have not shared it. It is important to provide a link to the protocol. Was the protocol for the review registered in PROSPERO or similar platform? What sort of studies were expected to be included in the review? Was there any deviation from the protocol at the end of the research?What informed the use of 1 ^st^ January 1957 as the cut-off date for the search?Given the increased research activity on immunization data, a search conducted up to December 2017 should be considered out of date for a paper submitted in March 2019. If the search is not updated, the authors should clearly identify this as a limitation.Quality assessment of included studies is essential. We cannot make a sound conclusion without knowing the quality of the included studies. If this is not done, the authors should identify this as a limitation.Are there particular reasons for not searching for grey literature? In studies with multiple antigens, what informed the choice of antigen that was included in the analysis?The authors should provide the complete search strategy used for one of the two databases, preferably Medline.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Dansereau

Emily
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We thank the reviewers very much for the time they have given to review the article and provide this constructive feedback.

*1. The authors indicate that they prepared a protocol for the review but have not shared it. It is important to provide a link to the protocol. Was the protocol for the review registered in PROSPERO or similar platform? What sort of studies were expected to be included in the review? Was there any deviation from the protocol at the end of the research?*

Thank you for noting the omission of our protocol. We have now added this to the OSF storage platform. We did not register it in a formal protocol platform; that is a good point of feedback for the future. We sought and received input from 20 experts on the protocol, including content matter experts as well as library science professionals. Our review and protocol were designed as an update and extension of the previous publication by Miles et al, which reviewed a similar set of literature through 2011. Therefore we expected that the publications would be of similar nature to those in the Miles study \-- however we extended our inclusion/exclusion criteria to capture a broader set of studies, by expanding the search terms, notably including to include data from serological surveys. We were able to stick fairly closely to our original protocol. We note the three deviations. First, we had originally thought to apply a slightly different search strategy for the period already covered by the Miles review (more narrow), and the period after (more broad) - however in the end we decided it was more comprehensive and consistent to apply a single set of broad search terms across the entire time period of interest. Second, though the protocol noted we would look for 'peer-reviewed published literature' this statement was inconsistent with the proposed search approach in the same protocol which included searching EMBASE, which includes grey literature including conference abstracts, and drawing on our expert network's knowledge of unpublished work -- the intention was always to include these sources. We opted to include 3 unpublished studies in the end -- (two from the Gavi Full Country Evaluations and one from an established research group working in Pakistan). The final change from original protocol was on the analysis side: after conducting the review, we decided it was not fitting to conduct a regression-based meta-analysis of the results as proposed, due to the heterogeneous nature of the studies included. We instead opted to focus on displaying and visualizing the results in a way that maximized interpretability for the readers, and synthesizing them descriptively.

*2. What informed the use of 1st January 1957 as the cut-off date for the search?*

Thank you for this question, and for catching an important typo in the manuscript. The start date was 1st January 1975, and date this was chosen because it aligned with the establishment of the EPI program. This has been corrected and explained in the updated manuscript.

*3. Given the increased research activity on immunization data, a search conducted up to December 2017 should be considered out of date for a paper submitted in March 2019. If the search is not updated, the authors should clearly identify this as a limitation.*

We agree and are glad to see this is an active area of research. This has now been noted as a limitation.

*4. Quality assessment of included studies is essential. We cannot make a sound conclusion without knowing the quality of the included studies. If this is not done, the authors should identify this as a limitation.*

Thank you for raising this important point. While we would have preferred to assess the study quality, it was difficult to do so with the information provided. WHO has work going forward to more clearly define quality criteria for coverage surveys, which would also help standardize the reporting. For the unpublished studies, we did take special effort to assess the quality of the work before deciding to include it in the paper, by speaking directly with the researchers to understand the design, implementation and limitations of their studies. This is now discussed in the limitations.

*5. Are there particular reasons for not searching for grey literature? *

As noted in the response to question 1, we did include grey literature from EMBASE and our expert network. This has now been clarified in the manuscript. We also acknowledge that our grey literature search may not have been comprehensive, and have added this as a limitation.  

*6. In studies with multiple antigens, what informed the choice of antigen that was included in the analysis?*

This is a good question and something we discussed at length. To maintain focus in the manuscript, we examined which were the most commonly reported antigens and doses across the studies, and opted to use those for the main analyses. However, we also had research questions about whether recall varied depending on the antigen or dose in question -- these questions could only be answered by papers reporting on multiple antigens and/or doses. For those analyses, we considered all antigens and doses presented in the study.

*7. The authors should provide the complete search strategy used for one of the two databases, preferably Medline.*

The detailed search syntax is included in the supplemental materials on OSF.

Thank you again for your review of our article.
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This is a great systematic review by Dansereau and colleagues examining the agreement of vaccination recall data, home-based records, health facility records, BCG scars and serological data in LMICs and I approve this article. This review is an updated and expanded version from one published by Miles *et al.*in 2013 and focuses on LMICs with some additional analyses. This article is timely given WHO\'s 2017 recommendation listing the reliability of vaccination recall a high research priority and given that the previous Miles *et al.* article only elicited 5 LMICs.

The article is written clearly and the methodology is also mostly clear and seems like it could be easily replicated. What was not entirely clear was the inclusion of grey literature as the article states the initial search for peer reviewed articles. However, manual reference searches and word-of-mouth experts provided means to include other articles; it was not entirely clear that grey literature was an inclusion criteria until reviewing the list of included articles. The article does list as a limitation that it may have missed some articles; however, one recommendation is the inclusion of specific antigen names in the search terms as this may have elicited more articles.

Overall, this was a well-written and timely article with interesting and thorough analyses including the following variability factors: coverage level, antigen, number of doses, age of child, vaccine schedule complexity and demographic factors.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Dansereau

Emily
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Thank you very much for the time and thought given to review our article. 

The reviewer is correct - we did include grey literature from EMBASE and our expert network, and this was not properly described in the manuscript. This has now been clarified in the manuscript. We also acknowledge that our grey literature search may not have been comprehensive, and have added this as a limitation.  

Many thanks again for the thoughtful review.
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